NYSEAMERICAN:TRXC TransEnterix Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TransEnterix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.37 0.00 (-1.32 %) (As of 09/18/2020 09:06 PM ET) Add Compare Share Today's Range$0.37Now: $0.37▼$0.3950-Day Range N/A52-Week Range$0.28Now: $0.37▼$10.40Volume1.50 million shsAverage Volume3.58 million shsMarket Capitalization$36.70 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for TransEnterix. Previous Next 2.3 Community Rank Outperform VotesTransEnterix has received 452 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTransEnterix has received 516 “underperform” votes. (Add your “underperform” vote.)Community SentimentTransEnterix has received 53.31% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote “Outperform” if you believe TRXC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTransEnterix does not currently pay a dividend.Dividend GrowthTransEnterix does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransEnterix insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Medical Instruments & Supplies Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:TRXC Previous Symbol CUSIPN/A CIK876378 Webwww.transenterix.com Phone+1-919-7658400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares99,876,000Market Cap$36.70 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $0.37 0.00 (-1.32 %) (As of 09/18/2020 09:06 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TRXC News and Ratings via Email Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter. TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of TransEnterix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix. When is TransEnterix's next earnings date? TransEnterix is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for TransEnterix. How were TransEnterix's earnings last quarter? TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its quarterly earnings results on Wednesday, August, 5th. The medical instruments supplier reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.17. The medical instruments supplier earned $0.66 million during the quarter, compared to analysts' expectations of $0.29 million. View TransEnterix's earnings history. Are investors shorting TransEnterix? TransEnterix saw a increase in short interest in August. As of August 31st, there was short interest totaling 4,860,000 shares, an increase of 23.7% from the August 15th total of 3,930,000 shares. Based on an average trading volume of 5,850,000 shares, the short-interest ratio is currently 0.8 days. Currently, 5.3% of the company's stock are short sold. View TransEnterix's Short Interest. Who are some of TransEnterix's key competitors? Some companies that are related to TransEnterix include Milestone Scientific (MLSS), Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), American Medical Technologies (ADLI), Ansell (ANSLF), Ansell (ANN), ANSELL LTD/S (ANSLY) and Borqs Technologies (BTAVF). View all competitors. What other stocks do shareholders of TransEnterix own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), Actinium Pharmaceuticals (ATNM), XOMA (XOMA), Geron (GERN), Opko Health (OPK), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Who are TransEnterix's key executives? TransEnterix's management team includes the following people: Mr. Todd M. Pope, CEO, Pres & Director (Age 53)Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52) What is TransEnterix's stock symbol? TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC." Who are TransEnterix's major shareholders? TransEnterix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bridgeway Capital Management Inc. (0.28%), Bank of America Corp DE (0.12%), Jane Street Group LLC (0.06%), Verition Fund Management LLC (0.11%) and AQR Capital Management LLC (0.05%). Company insiders that own TransEnterix stock include Andrea Biffi, Joseph P Slattery, William N Starling Jr and William N Starling, Jr. View institutional ownership trends for TransEnterix. Which institutional investors are buying TransEnterix stock? TRXC stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Verition Fund Management LLC, AQR Capital Management LLC, Bank of America Corp DE, and Jane Street Group LLC. View insider buying and selling activity for TransEnterix. How do I buy shares of TransEnterix? Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TransEnterix's stock price today? One share of TRXC stock can currently be purchased for approximately $0.37. How big of a company is TransEnterix? TransEnterix has a market capitalization of $36.70 million. What is TransEnterix's official website? The official website for TransEnterix is www.transenterix.com. How can I contact TransEnterix? TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400. This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
